Nebenjob Fahr- und Kurierdienste

Engagiert, zuverlässig, flexibel und sehr gute Englischkenntnisse?
Dann suchen wir Sie!

Eintrag vom 19.03.2019

Aufgabenstellung:

  • Chauffieren der Geschäftsleitung sowie Kunden und Gäste des Hauses
  • Kurier- und Botenfahrten

Sie verfügen über folgende Fähigkeiten, Erfahrungen und Kenntnisse:

  • Gültiger Führerschein der Klasse B
  • Mindestens 2 Jahre Fahrpraxis
  • Bereitschaft zum Einsatz an Werk-, Sonn- und Feiertagen
  • Reise- und Flugbereitschaft
  • Perfekte Umgangsformen, Kommunikationsbereitschaft, Zuverlässigkeit, und hohe Flexibilität
  • Sehr gute Deutsch- und Englischkenntnisse

Arbeitsbedingungen:

  • Arbeitsstunden nach Aufwand
  • Beginn: ab sofort
  • Vergütung: nach Rücksprache
  • Ausübungsort: In- und Ausland

Wenn Sie Spaß daran haben, in einem jungen engagierten Team mitzuarbeiten freuen wir uns auf Ihre Bewerbung.

TICEBA GmbH
Tissue & Cell Banking
Im Neuenheimer Feld 517
69120 Heidelberg, Deutschland
E bewerbung@ticeba.com

Privacy policy:
By submitting your application by post or email, you expressly agree that TICEBA GmbH may collect, process and use the data transmitted by you for the purpose of processing the application and that you have taken note of our privacy policy. You can revoke your consent at any time via email to office@ticeba.com.

« back

News
Coronavirus and Mesenchymal Stem Cells

Therapy for Pneumonia Patients iInfected by 2019 Novel Coronavirus

Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019(COVID-19)

Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus

Article about our study with limbal stem cells

On the website of the Harvard Stem Cell Institute you will find the following news release about the ongoing clinical trial conducted by our daughter company RHEACELL in patients suffering from limbal stem cell deficiency: Restoring vision: A stem cell therapy for cornea regeneration reaches the clinical-trial stage.

Clinical Trial - EB

The international phase I/IIa clinical trial has been approved by the U.S. Food and Drug Administration (FDA) and several European competent national regulatory authorities. The medicinal drug product tested in this trial has recently been granted Orphan Drug designation from the FDA and the European Medicines Agency (EMA) for the treatment of EB.

Clinical Trial - LSCD

The international phase I/IIa clinical trial has been approved by the U.S. Food and Drug Administration (FDA) and the German regulatory authority (Paul Ehrlich Institute). The medicinal drug product tested in this trial has recently been granted Orphan Drug designation from the FDA and the European Medicines Agency (EMA) and Fast Track designation from the FDA for the treatment of LSCD.

Safety

In a comprehensive preclinical study program, safety and local tolerability of ABCB5+ MSCs following subcutaneous, intramuscular and intravenous application has been demonstrated (Tappenbeck et al., 2019).

Newsletter